MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/lary.70037

Медицинская библиотека · The Laryngoscope · 2025

Effectiveness and Safety of Dupilumab Monotherapy in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyps.

Fujieda Shigeharu, Takabayashi Tetsuji, Ohta Nobuo, Yoshikawa Mamoru, Kibe Yuki, Ishida Masato, Suzuki Katsuhisa, Takahashi Yoshinori, Amin Nikhil, Wright Lakiea, Robinson Lacey, Yahata Kenji

Клиническое исследование IV фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

The randomized, double-blind, placebo-controlled LIBERTY SINUS-24 and SINUS-52 studies demonstrated that dupilumab is effective for chronic rhinosinusitis with nasal polyps (CRSwNP) when used with an intranasal corticosteroid (INCS); however, INCSs are not approved for CRSwNP in Japan. The current study aimed to investigate the effectiveness and safety of dupilumab monotherapy in Japanese individuals with CRSwNP.

METHODS

This phase 4, open-label, single-arm, multicenter study enrolled adult individuals with CRSwNP inadequately controlled with standard care therapies, including systemic corticosteroids and/or surgery. Subcutaneous dupilumab 300 mg was administered every 2 weeks; in participants with stable disease at week 24 (improvement of ≥ 2 points in the Nasal Polyp Score [NPS] from baseline at weeks 16 and 24), the dosing interval could be modified to every 4 weeks. The primary endpoint was the proportion of responders at week 24.

RESULTS

The study included 25 individuals with CRSwNP (mean ± standard deviation age of 53.4 ± 13.6 years; 60.0% male). At week 24, 23 participants (92.0%) were considered responders to dupilumab. Reductions from baseline to week 24 in bilateral endoscopic NPS (mean change -2.4), nasal congestion severity score (-1.58), and Lund-Mackay scores (-5.6) were observed with dupilumab. Dupilumab was well tolerated; over 52 weeks, 16 participants (69.6%) experienced a treatment-emergent adverse event (TEAE). Most TEAEs were mild in severity; moderate and severe TEAEs were reported in five (21.7%) and one (4.3%) participant, respectively.

CONCLUSION

Dupilumab monotherapy was effective and well tolerated in Japanese individuals with symptomatic CRSwNP.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05049122.

Для цитирования: Fujieda Shigeharu, Takabayashi Tetsuji, Ohta Nobuo, Yoshikawa Mamoru, Kibe Yuki, Ishida Masato, Suzuki Katsuhisa, Takahashi Yoshinori, Amin Nikhil, Wright Lakiea, Robinson Lacey, Yahata Kenji. Effectiveness and Safety of Dupilumab Monotherapy in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyps.. The Laryngoscope. 2025. DOI: 10.1002/lary.70037.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.